Liver Int

TAF shows lower HCC risk than TDF in chronic hepatitis B

November 13, 2025

A large propensity-matched analysis of >54,000 chronic hepatitis B patients found tenofovir alafenamide (TAF) was associated with a significantly lower incidence of hepatocellular carcinoma (HCC) compared with tenofovir disoproxil fumarate (TDF) (7.5 vs. 9.9 per 1000 person-years; subdistribution hazard ratio [SHR], 0.76; p<0.001). The hepatoprotective effect against HCC was seen even in pateints with cirrhosis (SHR, 0.78; p=0.003).

Clinical takeaway: Consider TAF over TDF for hepatitis B patients requiring long-term therapy, especially those at elevated risk for HCC or liver complications.

Source:

Yang J, et al. (2025, October 29). Liver Int. Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate. https://pubmed.ncbi.nlm.nih.gov/40995685/